| scholarly article | Q13442814 |
| P50 | author | Samir Mitragotri | Q7409527 |
| Aaron C Anselmo | Q42816187 | ||
| P2860 | cites work | Cancer immunotherapy: moving beyond current vaccines | Q24548229 |
| Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform | Q24596232 | ||
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Adoptive T cell therapy for cancer in the clinic | Q24680405 | ||
| Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities | Q27011598 | ||
| Cell-based drug delivery | Q28257039 | ||
| Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
| Monocyte and macrophage heterogeneity | Q29547438 | ||
| TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties | Q29547848 | ||
| Central memory and effector memory T cell subsets: function, generation, and maintenance | Q29615097 | ||
| Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm | Q29615517 | ||
| Nanocarriers as an emerging platform for cancer therapy | Q29616699 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Monocyte recruitment during infection and inflammation | Q29620067 | ||
| Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions | Q30543404 | ||
| Dendritic cell vaccines for cancer immunotherapy | Q33540299 | ||
| Red blood cell-mimicking synthetic biomaterial particles | Q33564678 | ||
| Freely suspended cellular "backpacks" lead to cell aggregate self-assembly | Q33596278 | ||
| NK cell-based immunotherapy for malignant diseases | Q33827433 | ||
| Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease | Q33892744 | ||
| Collagen-platelet rich plasma hydrogel enhances primary repair of the porcine anterior cruciate ligament | Q34000101 | ||
| Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. | Q34028841 | ||
| Therapeutic cell engineering with surface-conjugated synthetic nanoparticles | Q34112602 | ||
| Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. | Q46417574 | ||
| Macrophage depletion induced by clodronate-loaded erythrocytes. | Q46432782 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients | Q48030305 | ||
| Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. | Q49238618 | ||
| Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. | Q53385002 | ||
| Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes | Q57779762 | ||
| The first recorded blood transfusions: 1656 to 1668 | Q68515425 | ||
| Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity | Q71563753 | ||
| Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model | Q71677694 | ||
| Methanol detoxification by enzyme-loaded erythrocytes | Q72748415 | ||
| Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: immunogenicity and protection in mice | Q73315957 | ||
| Mechanisms initiating platelet thrombus formation | Q73447586 | ||
| Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes | Q73621576 | ||
| Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease | Q73691992 | ||
| The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study | Q74412146 | ||
| Surface functionalization of living cells with multilayer patches | Q83653405 | ||
| Bioactive polyelectrolyte multilayers: hyaluronic acid mediated B lymphocyte adhesion | Q84959285 | ||
| Cell surface negativity and the binding of positively charged particles | Q93699949 | ||
| Long-circulating and target-specific nanoparticles: theory to practice | Q34253450 | ||
| A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. | Q34708838 | ||
| Cell-mediated drug delivery. | Q34709440 | ||
| Cytotoxic T lymphocytes: all roads lead to death | Q34716318 | ||
| B lymphocytes: how they develop and function. | Q34813171 | ||
| Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. | Q35001971 | ||
| Platelet-rich plasma: from basic science to clinical applications | Q35010398 | ||
| Carrier erythrocytes: an overview | Q35055323 | ||
| Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials | Q35142623 | ||
| Adoptive-cell-transfer therapy for the treatment of patients with cancer | Q35210008 | ||
| Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease | Q35702733 | ||
| Adhesion mechanisms regulating the migration of monocytes | Q35790360 | ||
| Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. | Q35825254 | ||
| Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles | Q36319725 | ||
| Platelet mimetic particles for targeting thrombi in flowing blood | Q36355586 | ||
| Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. | Q36420900 | ||
| Engineering antigens for in situ erythrocyte binding induces T-cell deletion | Q36512070 | ||
| Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. | Q36874456 | ||
| Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting | Q36939901 | ||
| A macrophage-nanozyme delivery system for Parkinson's disease | Q37179637 | ||
| Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. | Q37395149 | ||
| Drug delivery by red blood cells: vascular carriers designed by mother nature | Q37700751 | ||
| Strategies in the design of nanoparticles for therapeutic applications | Q37771241 | ||
| Bio-inspired, bioengineered and biomimetic drug delivery carriers | Q37896455 | ||
| The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. | Q38128105 | ||
| Bringing natural killer cells to the clinic: ex vivo manipulation | Q38169643 | ||
| Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles | Q38525935 | ||
| Cell-based drug delivery devices using phagocytosis-resistant backpacks | Q39583293 | ||
| Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways | Q39885361 | ||
| Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells | Q40371833 | ||
| Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells | Q40498116 | ||
| Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. | Q41602044 | ||
| Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles | Q42234959 | ||
| Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes | Q43441843 | ||
| Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model | Q44198262 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 531-541 | |
| P577 | publication date | 2014-04-18 | |
| P1433 | published in | Journal of Controlled Release | Q6295046 |
| P1476 | title | Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles | |
| P478 | volume | 190 |
| Q39117236 | A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles |
| Q38557650 | Applying nanomedicine in maladaptive inflammation and angiogenesis |
| Q64917058 | Biodistribution and sensitive tracking of immune cells with plasmonic gold nanostars. |
| Q47295354 | Cell-Based Drug Delivery and Use of Nano-and Microcarriers for Cell Functionalization. |
| Q89947757 | Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy |
| Q50245883 | Co-Assembly of Heparin and Polypeptide Hybrid Nanoparticles for Biomimetic Delivery and Anti-Thrombus Therapy |
| Q61446927 | Coatings on mammalian cells: interfacing cells with their environment |
| Q27002209 | Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines |
| Q64068450 | DNA Nanotechnology Enters Cell Membranes |
| Q92581015 | Engineering Cell Membrane-Based Nanotherapeutics to Target Inflammation |
| Q60923345 | Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy |
| Q50426810 | Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. |
| Q92257562 | Impact of Nanocapsules on Red Blood Cells Interplay Jointly Assessed by Optical Tweezers and Microscopy |
| Q28080427 | Improving cell-based therapies by nanomodification |
| Q47215416 | Inhibition of cancer cell migration with CuS@ mSiO2-PEG nanoparticles by repressing MMP-2/MMP-9 expression |
| Q39159035 | Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. |
| Q101137932 | Leukocyte-mimetic liposomes penetrate into tumor spheroids and suppress spheroid growth by encapsulated doxorubicin |
| Q55068369 | Macrophage-mediated delivery of light activated nitric oxide prodrugs with spatial, temporal and concentration control. |
| Q38827940 | Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy. |
| Q98466570 | Micro Versus Macro - The Effect of Environmental Confinement on Cellular Nanoparticle Uptake |
| Q26827999 | Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency |
| Q38871242 | Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer |
| Q50070105 | Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy |
| Q49351130 | Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells |
| Q90373758 | Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery |
| Q58122856 | Nanoparticle-Laden Macrophages for Tumor-Tropic Drug Delivery |
| Q47707153 | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. |
| Q52840157 | Next generation drug delivery: circulatory cells-mediated nanotherapeutic approaches. |
| Q36703526 | Non-affinity factors modulating vascular targeting of nano- and microcarriers |
| Q91632617 | Paclitaxel-Loaded Macrophage Membrane Camouflaged Albumin Nanoparticles for Targeted Cancer Therapy |
| Q55192052 | Photoacoustic Imaging-Guided Photothermal Therapy with Tumor-Targeting HA-FeOOH@PPy Nanorods. |
| Q34579964 | Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries |
| Q47621457 | Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy |
| Q59812889 | Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy |
| Q38760096 | Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems |
| Q47133839 | Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors |
| Q38855296 | Synthesis of self-reporting polymeric nanoparticles for in situ monitoring of endocytic microenvironmental pH. |
| Q38598987 | Targeted endothelial nanomedicine for common acute pathological conditions |
| Q28550941 | The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells |
| Q41348178 | The species origin of the serum in the culture medium influences the in vitro toxicity of silica nanoparticles to HepG2 cells. |
Search more.